Holen Sie sich die Stockscreener-App
84.08
0.83%
0.69
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$83.39
Offen:
$82.55
24-Stunden-Volumen:
3.14M
Relative Volume:
0.71
Marktkapitalisierung:
$49.36B
Einnahmen:
$5.88B
Nettoeinkommen (Verlust:
$1.34B
KGV:
35.80
EPS:
2.3489
Netto-Cashflow:
$799.60M
1W Leistung:
+1.22%
1M Leistung:
+13.71%
6M Leistung:
+14.12%
1J Leistung:
+26.95%
1-Tages-Spanne:
$82.01
$84.16
1-Wochen-Bereich:
$81.69
$84.83
52-Wochen-Spanne:
$64.89
$87.09
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
84.08 | 48.39B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
125.89 | 219.72B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.27B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.02 | 136.15B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
92.66 | 118.26B | 34.20B | 4.69B | 5.30B | 3.6218 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Edwards Lifesciences Stock: Is Wall Street Bullish or Bearish? - Barchart.com
Edwards Lifesciences Insider Sold Shares Worth $1,080,093, According to a Recent SEC Filing - MarketScreener
Acadian Asset Management LLC Buys 316,977 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW): Exploring Valuation as Earnings Upgrades and Guidance Fuel Options Market Volatility - Yahoo Finance UK
Edwards Lifesciences CVP Lippis sells $84,196 in stock - Investing.com
Edwards Lifesciences CFO Ullem sells $1m in shares - Investing.com
Aortic Innovations LLC v. Edwards Lifesciences Corp. (Fed. Cir. 2025) - JD Supra
Edwards backs AHA’s heart valve disease initiative - MassDevice
Will Edwards Lifesciences Corporation (EWL) stock test record highs in 2025Market Sentiment Review & Safe Swing Trade Setup Alerts - newser.com
Edwards Lifesciences Corporation stock trend forecastPortfolio Return Report & Verified Chart Pattern Trade Signals - newser.com
Why Edwards Lifesciences Corporation stock attracts HNW investors2025 Price Targets & AI Enhanced Trading Signals - newser.com
Will Edwards Lifesciences Corporation stock outperform foreign stocksWeekly Trend Report & Low Risk High Win Rate Stock Picks - newser.com
Mitsubishi UFJ Asset Management Co. Ltd. Acquires 65,337 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Aviva PLC Trims Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
What does recent volatility data suggest for Edwards Lifesciences CorporationWeekly Trading Summary & AI Optimized Trade Strategies - newser.com
Will Edwards Lifesciences Corporation stock return to pre crash levelsJuly 2025 Trends & Consistent Profit Trade Alerts - newser.com
Edwards (NYSE: EW) is founding sponsor of AHA Heart Valve Initiative with five-year plan - Stock Titan
Resona Asset Management Co. Ltd. Raises Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Andra AP fonden - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Is Edwards Lifesciences Corporation (EWL) stock positioned for secular growthJuly 2025 Market Mood & Real-Time Chart Pattern Alerts - newser.com
What dividend safety score for Edwards Lifesciences Corporation stockJuly 2025 Market Mood & Breakout Confirmation Alerts - newser.com
Daiwa Securities Adjusts Price Target on Edwards Lifesciences to $99 From $89, Maintains Buy Rating - MarketScreener
Using data models to predict Edwards Lifesciences Corporation stock movementPortfolio Value Report & Accurate Trade Setup Notifications - newser.com
Bank of Montreal Can Lowers Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Real time scanner hits for Edwards Lifesciences Corporation explainedPortfolio Value Report & Risk Controlled Swing Alerts - newser.com
Can Edwards Lifesciences Corporation stock sustain institutional interestTrade Analysis Report & Weekly High Return Stock Forecasts - newser.com
FTC Wants 'Tainted' Drs. Testimony Barred From Merger Case - Law360
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Do Options Traders Know Something About Edwards Lifesciences Stock We Don't? - Nasdaq
EW (Edwards Lifesciences) EV-to-Revenue : 7.74 (As of Nov. 05, 2025) - GuruFocus
What is the fair value estimate for Edwards Lifesciences Corporation (EWL) stock in 2025July 2025 Final Week & Expert Approved Trade Ideas - newser.com
Is the Options Market Predicting a Spike in Edwards Lifesciences Stock? - Nasdaq
Edwards Lifesciences Corporation $EW Shares Sold by Huntington National Bank - MarketBeat
Edwards Lifesciences Corp. Hits New 52-Week High at $87.09 - Markets Mojo
Edwards Lifesciences Corporation (NYSE:EW) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
How Edwards Lifesciences Corporation stock reacts to new regulationsQuarterly Trade Summary & Free Safe Entry Trade Signal Reports - newser.com
Edwards Lifesciences’ ALTERRA Study: A Potential Game-Changer in Heart Valve Treatment - MSN
Edwards Lifesciences (NYSE:EW) Given New $90.00 Price Target at Truist Financial - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Bank of New York Mellon Corp - MarketBeat
Wellington Shields Capital Management LLC Sells 5,700 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
EPO and UPC align in decision to uphold Edwards Lifesciences’ heart valve patent - JUVE Patent
36,530 Shares in Edwards Lifesciences Corporation $EW Purchased by Burney Co. - MarketBeat
What is the fair value of Edwards Lifesciences Corporation stock nowMarket Risk Summary & Fast Moving Market Watchlists - newser.com
Envestnet Asset Management Inc. Has $26.61 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Truist Securities Maintains Edwards Lifesciences (EW) Rating, Ra - GuruFocus
Bernstein Adjusts Price Target on Edwards Lifesciences to $90 From $85 - MarketScreener
Bernstein raises Edwards Lifesciences stock price target to $90 on TAVR growth - Investing.com
Canaccord Genuity raises Edwards Lifesciences stock price target on solid Q3 - Investing.com
Raymond James upgrades Edwards Lifesciences stock rating to Outperform By Investing.com - Investing.com Canada
Machina Capital S.A.S. Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):